Studieoverzicht

Study name: KRASCENDO

Histology	NSCLC
Tumor stage	Stage IV
Host / recruiting sites	Radboud UMC
Enrollment	Recruiting
Therapy line	First line (1L)
Design	This is an open-label, multicenter Phase Ib/II study designed to evaluate the safety, pharmacokinetics and activity of divarasib in combination with other cancer-therapies with untreated advanced or metastatic NSCLC that harbors a KRAS G12C mutation.
Intervention	Cohort A: Divarasib + Pembrolizumab Cohort B: Divarasib + Pembrolizumab + Platinum-based chemotherapy + Pemetrexed
Key inclusion criteria	Unresectable advanced or metastatic KRAS G12C+ NSCLC Non-squamous Treatment naïve
Key exclusion criteria	Known concomitant second driver mutation with available targeted treatment. Squamous cell histology, mixed tumors. Symptomatic, untreated or actively progressing CNS metastases
Contact information	Log in voor de contactinformatie